- Home
- LIQT vs KZIA Comparison
LIQT vs KZIA Comparison
Compare LIQT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- KZIA
- Stock Information
- Founded
- LIQT 2004
- KZIA 1994
- Country
- LIQT Denmark
- KZIA Australia
- Employees
- LIQT N/A
- KZIA N/A
- Industry
- LIQT Industrial Machinery/Components
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- LIQT Technology
- KZIA Health Care
- Exchange
- LIQT Nasdaq
- KZIA Nasdaq
- Market Cap
- LIQT 16.1M
- KZIA 5.1M
- IPO Year
- LIQT N/A
- KZIA 1999
- Fundamental
- Price
- LIQT $1.86
- KZIA $11.43
- Analyst Decision
- LIQT Strong Buy
- KZIA Strong Buy
- Analyst Count
- LIQT 2
- KZIA 2
- Target Price
- LIQT $4.80
- KZIA $14.00
- AVG Volume (30 Days)
- LIQT 29.0K
- KZIA 705.9K
- Earning Date
- LIQT 08-13-2025
- KZIA 07-22-2025
- Dividend Yield
- LIQT N/A
- KZIA N/A
- EPS Growth
- LIQT N/A
- KZIA N/A
- EPS
- LIQT N/A
- KZIA N/A
- Revenue
- LIQT $14,986,815.00
- KZIA $1,549,158.00
- Revenue This Year
- LIQT $36.89
- KZIA N/A
- Revenue Next Year
- LIQT $16.33
- KZIA N/A
- P/E Ratio
- LIQT N/A
- KZIA N/A
- Revenue Growth
- LIQT N/A
- KZIA 248983.08
- 52 Week Low
- LIQT $1.34
- KZIA $2.86
- 52 Week High
- LIQT $3.20
- KZIA $40.75
- Technical
- Relative Strength Index (RSI)
- LIQT 65.61
- KZIA 76.27
- Support Level
- LIQT $1.74
- KZIA $5.86
- Resistance Level
- LIQT $1.88
- KZIA $11.34
- Average True Range (ATR)
- LIQT 0.12
- KZIA 1.11
- MACD
- LIQT 0.03
- KZIA 0.38
- Stochastic Oscillator
- LIQT 93.90
- KZIA 90.76
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.